Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

30,181 total articles

Raymond James Refreshes August Healthcare Picks, Adds Aveanna, Carriage Services and Viking Therapeutics

Raymond James Refreshes August Healthcare Picks, Adds Aveanna, Carriage Services and Viking Therapeutics

Raymond James updated its monthly shortlist for the healthcare sector, adding Aveanna Healthcare, Carriage Services and Viking Therapeutics. The investment bank emphasized imminent earnings dates and upcoming clinical readouts as the primary catalysts that could shape investor sentiment in the near term. Aveanna was added ahead of an August 13 earn…

Pentagon Orders Emergency Session on Munitions Shortfall After Trump Call

Pentagon Orders Emergency Session on Munitions Shortfall After Trump Call

The Pentagon's second-ranking official convened an urgent meeting on Friday night after a phone call from President Donald Trump, according to reports citing multiple sources. Senior military and defense acquisition leaders discussed immediate options to address a reported decline in U.S. weapon stockpiles linked to the Iran war. The meeting follow…

OCBC Offers the Best Value-Quality Mix Among Singapore’s Big Three Banks

OCBC Offers the Best Value-Quality Mix Among Singapore’s Big Three Banks

All three major Singapore banks deliver yields above 4% and solid franchises, but differences in valuation and recent performance point to OCBC as the most compelling risk-adjusted opportunity. OCBC shows the highest fair-value upside at +15.2% supported by the strongest net income margin and low volatility. UOB appears cheapest on multiples but re…

Nikita Bier Exits Product Lead Role at X After Just Over a Year

Nikita Bier Exits Product Lead Role at X After Just Over a Year

Nikita Bier has stepped down as head of product at X after a tenure of slightly more than a year. He will continue to advise the company after overseeing the roll-out of 30 new products and framing efforts to preserve what he called the "integrity of the town square." His departure comes amid controversies involving the platform's Grok chatbot and …

Nintendo Q1 Preview: Switch 2 Momentum Tested by Soaring Memory Prices

Nintendo Q1 Preview: Switch 2 Momentum Tested by Soaring Memory Prices

Nintendo reports first-quarter results for fiscal 2027 on Aug 6, with consensus estimates at ¥440.75 billion in revenue and ¥64.54 EPS. Investors will be watching whether sales momentum behind Switch 2 is sufficient to withstand a substantial increase in memory-chip costs, a factor that has pressured margins amid a market valuation that is -44.63% …

Duolingo Shares Slide After Revenue Guidance Comes Up Short

Duolingo Shares Slide After Revenue Guidance Comes Up Short

Duolingo reported stronger-than-expected second-quarter operating metrics and adjusted earnings, but a Q3 revenue forecast and updated full-year guidance that slightly trailed analyst estimates sent the stock sharply lower in after-hours trading. Management emphasized user growth over near-term monetization, while an earlier analyst downgrade added…

FDA Clears Takeda’s First-in-Class Oral Therapy for Narcolepsy Type 1

FDA Clears Takeda’s First-in-Class Oral Therapy for Narcolepsy Type 1

The U.S. Food and Drug Administration has approved Takeda Pharmaceutical’s oral medication for narcolepsy type 1, marking the first approved therapy to directly address the orexin deficiency that underlies the disorder. The decision relied on clinical trials showing daytime wakefulness improvements versus placebo. Final U.S. patient access will dep…